PT02. - COMPLIANCE WITH KETOGENIC DIET IN PATIENTS UNDERGOING RADIOTHERAPY FOR PELVIC CANCERS: A PROSPECTIVE, RANDOMIZED STUDY

PT02.

COMPLIANCE WITH KETOGENIC DIET IN PATIENTS UNDERGOING RADIOTHERAPY FOR PELVIC CANCERS: A PROSPECTIVE, RANDOMIZED STUDY

M. Cintoni^1,2,*, E. Leonardi¹, P. C. Raoul¹, C. De Rossi¹, M. Palombaro¹, E. Rinninella^1,2, M. Di Virgilio¹, F. Grassi¹, G. Egidi¹, R. Autorino³, M. Campitelli³, R. M. Rinaldi³, V. De Luca³, G. Chiloiro³, M. A. Gambacorta³, A. Gasbarrini^2,4, M. C. Mele^1,2

¹UOC di Nutrizione Clinica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, ²Centro di Ricerca e Formazione in Nutrizione Umana, Università Cattolica Del Sacro Cuore, ³UOC di Radioterapia Oncologica, ⁴UOC di Medicina interna, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Rationale: The Ketogenic Diet (KD), characterized by standard protein levels, minimal carbohydrate intake, and elevated fat content, has recently gained attention as a promising approach to preserving muscle mass in cancer patients receiving radiotherapy.

This research seeks to evaluate the compliance rate and efficacy of KD to improve cancer therapy outcomes by enhancing therapy tolerance and minimizing muscle loss.

Methods: The KOMPARC study is a prospective, randomized, mono-centric trial designed to investigate the impact of KD on individuals receiving radiotherapy for pelvic tumors.

Before treatment starts, participants are randomized into two groups: one following the KD and the other adhering to a standard diet (SD) based on ESPEN recommendations.

A post-treatment evaluation is then scheduled to reassess the baseline parameters and assess the outcomes.

The main goal is to compare compliance with the dietary protocols, while secondary objectives focus on changes in body composition, preservation of Body cell mass (BCM), treatment toxicities, and safety

Results: 28 patients completed the treatment (KD: 39.3%; SD: 60.7%) with a comparable interruption rate in the groups (45.4% for KD, 31,6% for SD; p: 0.59).

Weight had a trend of reduction in KD (71.9 vs 71.4; p 0.07) and had a significant reduction in SD (67.1 vs 65.7; p: 0.03). PhA remained stable in both groups; BCM remained stable in the KD group but slightly decreased in the SD group. Gastrointestinal toxicities (CTCAE v5.0) results comparable between the two groups (80.0% KD vs 70.6%; p: 0.59), as well as genitourinary (p:0.56), and fatigue (p:0.52).

Conclusion: Overall, the KD appears as well-tolerated as the SD; however, more data must be gathered to determine its effects on body composition, treatment toxicities, and oncological outcomes.

Disclosure of Interest: None declared